β-lactamase producing Pseudomonas aeruginosa in hospitalised patients

Indian Journal of Pathology and Microbiology

Volumn 48, Issue 4, 2005, Pages 530-533

  Pandey, Anita ^a   Malenie, Renuka ^a   Asthana, Ashish K ^a  

^a SUBHARTI MEDICAL COLLEGE   (India)

Author keywords

Extended spectrum beta lactamase; Nosocomial infection; P. aeruginosa

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAMASE; CEFOPERAZONE; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; NALIDIXIC ACID; PIPERACILLIN; SULBACTAM; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE PREDISPOSITION; HOSPITALIZATION; NONHUMAN; PREVALENCE; PSEUDOMONAS AERUGINOSA;

BETA-LACTAMASES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HOSPITALIZATION; HUMANS; INDIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 28844459100     PISSN: 03774929     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Trafny EA. Susceptibility of adherent organisms from P. aeruginosa and S. aureus strains isolated from burn wounds to antimicrobial agents. Int J Antimicrob Agents 1998; 10:223-8.
2. th ed. New York: McGraw Hill Companies Inc., 2001:963-70.
3. st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14(4):933-51.
4. Thomson KS. Controversies about extended spectrum and AmpC beta lactamases. Emerg Infect Dis 2001; 7(2):333-6.
5. Yares RR. New intervention strategies for reducing antibiotic resistance. Chest 1999; 115:245-75.
6. Ciofu O, Giwercman B, Pederson SS, Hoiby N. Development of antibiotic resistance in P. aeruginosa during two decades of antipseudomonal treatment at the Danish CF center. APMIS 1994; 102(9):674-80.
7. Mouton JW, den Hollander JG, Horrevorts AM. Emergence of antibiotic resistance among P. aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother 1993; 31(6):352-6.
8. Brown PD, Izundu A. Antibiotic resistance in clinical isolates of P. aeruginosa in Jamaica. Pan Am J Public Health 2004; 16(2):125-30.
9. Cheesbrough M. Medical laboratory manual for tropical countries. Doddington: Tropical Health Technology, 1984.
10. Jarlier V, Nicolas M, Fournier G et al. Extended broad-spectrum â-lactamases conferring transferable resistance to newer â - lactam agents in Enterobacteriaceae: Hospital prevalence and susceptibility pattern. Rev Infect Dis 1988; 10:867-78.
11. Nadal D, Von Gravenenitz A. Routine detection of inducible beta lactamase in Gram-negative bacilli by means of disc susceptibility testing. J Microbiol Methods 1993; 17:283-91.
12. th ed. Wayne: NCCLS, 2000:20(1):M2-A7.
13. Mahrez KB, Rejiba S, Belhadj C, Belhadj O. Beta lactamase-mediated resistance to extended spectrum cephalosporins among clinical isolates of P. aeruginosa. Res Microbiol 1999; 150:403-6.
14. Livermore DM. â lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8:557-84.
15. Singh NP, Goyal R, Manchanda V, Das S, Kaur I, Talwar V. Changing trends in bacteriology of burns in the burns unit, Delhi, India. Burn 2003; 29:129-32.
16. th Jan 2005, 65.
17. Mangala G, Pramod M, Kandle S et al. Correlation of extended spectrum beta lactamases production with cephalosporin resistance in Gram negative bacilli. Indian J Pathol Microbiol 2004; 47(1):82-4.
18. Babypadmini S, Appalaraju B. Extended spectrum â-lactamases in urinary isolates of Escherichia coli and Klebsiella pneumoniae-prevalence and susceptibility pattern in a tertiary care hospital. Indian J Med Microbiol 2004; 22(3):172-4.
19. Purva M, Arti K, Bimal D, Benu D. Prevalence of extended spectrum â lactamase producing Gram-negative bacteria in a tertiary care hospital. Indian J Med Res 2002; 115:153-7.
20. Ahmed I, Salam A. Extended spectrum a lactamases and bacterial resistance. Pak J Med Sci 2002; 18(2):151-5.